Diabetes | Omnihealth Practice

News & Perspective

Real-world experience of ultra-long basal insulins complements the clinical trial findings

01 Aug,2018

Insulin degludec (IDeg) and insulin glargine 300U/mL (IGlar-U300) represent the latest developments in insulin therapy, seeking to extend the duration of action beyond 24 hours, but with a flat peak action profile and lower variability.1 At the 23rd Hong Kong Medical Forum (HKMF) hosted by the Unive...

It’s not about better HbA1c in the medical record, it’s about survival and QoL improvement

01 Aug,2018

The completed cardiovascular outcomes trials (CVOTs) for the sodium-glucose cotransporter 2 (SGLT2) inhibitors have yielded important information regarding the potential CV benefits of the drug class. At the 23rd Hong Kong Medical Forum (HKMF), Dr. Mikhail Kosiborod of Saint Luke's Mid America Heart...

SGLT2 inhibitors could ameliorate hepatic dysfunction through glycemic improvement

29 May,2018

The benefits of sodium-glucose co-transporter 2 (SGLT2) inhibitors beyond their glucose-lowering effect continue to expand. In a study that included type 2 diabetes patients at the Diabetes Clinic of Queen Mary Hospital, Prof. Karen Lam and the research team from the University of Hong Kong (HKU) an...

View all

Conference Update

SGLT2-inhibitors in type 1 diabetes: DKA risk can be different between agents

14 Dec,2017

Current therapeutic options for treating type 1 diabetes (T1DM) remain very limited, with insulin being the mainstay of therapy. However, the data presented at the European Association for the Study of Diabetes (EASD) 2017 Annual Meeting have revealed that selective sodium-glucose co-transporter 2 (...

Sustain-6: Semaglutide shows non-inferiority of cardiovascular outcomes to standard care in type 2 diabetes

10 Feb,2017

Semaglutide, a glucagon-like peptide (GLP)-1 agonist developed by Novo Nordisk, has demonstrated non-inferiority in cardiovascular (CV) risk, in fact, a 26% reduced composite risk of CV death, non-fatal myocardial infarction and non-fatal stroke, as compared to placebo in a cohort of >3,000 patie...

EMPA-REG: Empagliflozin delays renal disease progression in T2D

27 Jun,2016

EMPA-REG OUTCOME trial was the first positive FDA-mandated cardiovascular (CV) outcome study for anti-hyperglycemia medicine reported last fall.1 Yet, concerns remain as per whether empagliflozin, as one of the sodium-glucose transporter 2 inhibitors (SGLT2i) that primarily exert glucose-lowering ef...

View all

Real-world experience of ultra-long basal insulins complements the clinical trial findings

01 Aug,2018

It’s not about better HbA1c in the medical record, it’s about survival and QoL improvement

01 Aug,2018

SGLT2 inhibitors could ameliorate hepatic dysfunction through glycemic improvement

29 May,2018

View all